The Metabolic Diseases Research Unit conducts research projects on diabetes. The different research projects carried out focus on type 1 diabetes and cystic fibrosis related diabetes. Some of our projects also address type 2 diabetes.
Type 1 diabetes accounts for approximately 10% of all cases and is usually diagnosed during childhood. Type 1 diabetes is generally treated by intensive insulin therapy using multiple daily injections or continuous subcutaneous insulin infusion pump. Despite available treatments, more than 60% of patients with type 1 diabetes do not achieve recommended glycemic (blood sugar) targets. Wide variations in sugar concentrations are observed and can lead to serious complications due to hyperglycemia (high blood sugar: damage to eyes, kidney and nerves) and hypoglycemia (low blood sugar: malaise and loss of consciousness).
The life expectancy of people with cystic fibrosis improves regularly. New major complications, such as cystic fibrosis related diabetes (high blood glucose levels), have emerged. The causes of cystic fibrosis related diabetes are not well established. The laboratory is attempting to shed light on the mechanisms involved in the development of cystic fibrosis related diabetes as well as on the association between high blood glucose levels and changes in weight and pulmonary function. The team also study various strategies to prevent or delay the development of cystic fibrosis related diabetes and its complications.
- Director, Metabolic Diseases research unit
- Director, Diabetes Clinic
- Director, research platform on obesity, metabolism and diabetes
- Full IRCM Research Professor
- Geographical full time associate professor, Department of Nutrition, Faculté de médecine, Université de Montréal
- Physician, Endocrinology Division, Medicine Department, CHUM
- Associate researcher, CHUM Research Centre
- Adjunct Professor, Department of Medicine (Division of Experimental Medicine), McGill University
- Holder of the J.A. DeSève Chair in clinical research
Awards and honours
- 2017 Research Award, from the FMSQ (Fédération des médecins spécialistes du Québec)
- 2015 IMS BROGAN Award, from the FMSQ (Fédération des médecins spécialistes du Québec)
- Three awards for excellence in teaching (2012, 2013-2014), Université de Montréal
- 2012 Pierre-Bois Excellence Award, IRCM Foundation
- 2010 Young Investigator Award, Canadian Society of Endocrinology and Metabolism
Projects and major discoveries
Development of an external artificial pancreas
Type 1 diabetes and exercise: strategies to reduce hypoglycemia
Caracterization of patients with type 1 diabetes and the metabolic syndrome
Cystic fibrosis related diabetes
Colomba J, Boudreau V, Lehoux-Dubois C, Desjardins K, Coriati A, Tremblay F, Rabasa-Lhoret R, The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity. - Journal Of Cystic Fibrosis : Official Journal Of The European Cystic Fibrosis Society 2019 Jan 30
Brassard D, Laramée C, Corneau L, Bégin C, Bélanger M, Bouchard L, Couillard C, Desroches S, Houle J, Langlois MF, Provencher V, Rabasa-Lhoret R, Vohl MC, Robitaille J, Lemieux S, Lamarche B, Poor Adherence to Dietary Guidelines Among French-Speaking Adults in the Province of Quebec, Canada: The PREDISE Study. - The Canadian Journal Of Cardiology 2018 Dec
Roy-Fleming A, Taleb N, Messier V, Suppère C, Cameli C, Elbekri S, Smaoui MR, Ladouceur M, Legault L, Rabasa-Lhoret R, Timing of insulin basal rate reduction to reduce hypoglycemia during late post-prandial exercise in adults with type 1 diabetes using insulin pump therapy: A randomized crossover trial. - Diabetes & Metabolism 2018 Aug 27
Dr. Rabasa-Lhoret actively participates to knowledge dissemination and continuing medical education. He has given more than 300 conferences up to now.
La Voix de L'Est - Some Canadians with type 1 diabetes can now more accurately control their blood sugar levels by using a pump that automatically adjusts their insulin dosage in real time.
Québec Science – What is the difference between type 1 and type 2 diabetes?
ICI Première (Les éclaireurs) – Over the past few years, the treatment of diabetes, which affects approximately 10% of the Canadian population, has been refined. Some very promising oral drugs are now on the market.
- J-A De Sève Foundation (research chair managed by IRCM)
- Canadian Institutes of Health Research (CIHR)
- National Institute of Health (NIH, United States)
- Juvenile Diabetes Research Foundation (Canada & international)
- Diabetes Canada
- Cystic Fibrosis Canada
- Cystic Fibrosis Foundation (United States)
- Société Francophone du Diabète (SFD)
- Fondation du grand Défi Pierre Lavoie, Corporation de rechercher et d’action sur les maladies héréditaires, Fondation pour la recherche médicale (scholarships for graduate students)
- Funds from pharmaceuticals companies for research initiated by the industry of y our research group.
- Donation from individuals or associations (Diabète Lanaudière, etc.)
Support biomedical research
Montreal Clinical Research Institute (IRCM)
110, des Pins Avenue West
Montréal, Québec H2W 1R7